Effectiveness of the Use of Three-Dose Intravitreal Ziv-Aflibercept in the Management of Diabetic Macular Edema in a Real-Life Setting

References

• Mansour AM, I Al-Ghadban S, Yunis MH, El-Sabban ME. Ziv-Aflibercept in macular disease. Br J Ophthalmol. 2015;99(8):1055–1059. doi:10.1136/bjophthalmol-2014-306319
   PubMed Web of Science ®Google Scholar
• Chhablani J, Narayanan R, Mathai A, et al. Short-term safety profile of intravitreal Ziv-Aflibercept. Retina. 2016;36(6):1126–1131. doi:10.1097/IAE.0000000000000913
   PubMed Web of Science ®Google Scholar
• De Andrade GC, De Oliveira Dias JR, Maia A, et al. Intravitreal injections of Ziv-Aflibercept for diabetic macular edema a pilot study. Retina. 2016;36(9):1640–1645. doi:10.1097/IAE.0000000000001000
   PubMed Web of Science ®Google Scholar
• Demirel S, Argo C, Agarwal A, et al. Updates on the clinical trials in diabetic macular edema. Middle East Afr J Ophthalmol. 2016;23(1):3–12. doi:10.4103/0974-9233.172293
   PubMed Web of Science ®Google Scholar
• Singh SR, Dogra A, Stewart M, et al. Intravitreal Ziv-Aflibercept: clinical effects and economic impact. Asia Pac J Ophthalmol. 2017;6(6):561–568.
   PubMedGoogle Scholar
• Barmas-Alamdari D, D’Souza HS, Kapoor KG, Wagner AL. Intravitreal Ziv-Aflibercept: a comprehensive review. Semin Ophthalmol. 2019;34(6):420–435. doi:10.1080/08820538.2019.1641526
   PubMed Web of Science ®Google Scholar
• Hernandez-Da Mota SE, Melo-Granados EAR, Fromow-Guerra J, et al. Correlation analysis of fundus autofluorescence, spectral domain optical coherence tomography, and visual function in patients with diabetic macular oedema treated with intravitreal Ziv-Aflibercept. Eur J Ophthalmol. 2019;29(3):271–277. doi:10.1177/1120672119833267
   PubMed Web of Science ®Google Scholar
• Jabbarpoor Bonyadi MH, Baghi A, Ramezani A, et al. One-year results of a trial comparing 2 doses of intravitreal Ziv-Aflibercept versus bevacizumab for treatment of diabetic macular edema. Ophthalmol Retina. 2018;2(5):428–440. doi:10.1016/j.oret.2017.09.010
   PubMedGoogle Scholar
• Mansour AM, Ashraf M, Charbaji A, et al. Two-year outcomes of intravitreal Ziv-Aflibercept. Br J Ophthalmol. 2018;102(10):1387–1390. doi:10.1136/bjophthalmol-2017-311591
   PubMed Web of Science ®Google Scholar
• Mansour AM, Stewart MW, Farah ME, et al. Ziv-Aflibercept: a cost-effective, off-label, highly potent antagonist of vascular endothelial growth factor. Acta Ophthalmol. 2020;98(5):e540–e548.
   PubMed Web of Science ®Google Scholar
• Singh SR, Stewart MW, Chattannavar G, et al. Safety of 5914 intravitreal ziv-aflibercept injections. Br J Ophthalmol. 2019;103(6):805–810. doi:10.1136/bjophthalmol-2018-312453
   PubMed Web of Science ®Google Scholar
• Mansour AM, Dedhia C, Chhablani J. Three-month outcome of intravitreal ziv-aflibercept in eyes with diabetic macular oedema. Br J Ophthalmol. 2017;101(2):166–169. doi:10.1136/bjophthalmol-2016-308679
   PubMed Web of Science ®Google Scholar
• Singh SR, Chattannavar G, Ayachit A, et al. Intravitreal Ziv-Aflibercept: safety analysis in eyes receiving more than ten intravitreal injections. Semin Ophthalmol. 2020;35(1):2–6. doi:10.1080/08820538.2019.1686528
   PubMed Web of Science ®Google Scholar
• Panozzo G, Cicinelli MV, Augustin AJ, et al. An optical coherence tomography-based grading of diabetic maculopathy proposed by an international expert panel: the European school for advanced studies in ophthalmology classification. Eur J Ophthalmol. 2020;30(1):8–18. doi:10.1177/1120672119880394
   PubMed Web of Science ®Google Scholar
• De Andrade GC, De Oliveira Dias JR, Maia A, et al. Intravitreal Ziv-Aflibercept for diabetic macular edema: 48-week outcomes. Ophthalmic Surg Lasers Imaging Retina. 2018;49(4):245–250. doi:10.3928/23258160-20180329-06
   PubMed Web of Science ®Google Scholar
• Meza-Anguiano A, Romo-García E, Gutiérrez-Ruiz GN, et al. Safety of short-term intravitreal use of ziv-aflibercept 2 mg in different retinal pathologies. Rev Mex Oftalmol. 2019;93(3):125–129.
   Google Scholar
• Braimah IZ, Amoaku WM. Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population. Eye. 2022;36(1):40–44. doi:10.1038/s41433-022-02005-6
   PubMed Web of Science ®Google Scholar
• Braimah IZ, Kenu E, Amissah-Arthur KN, Akafo S, Kwarteng KO, Amoaku WM. Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: a randomised double-blind intervention study. PLoS One. 2019;14(10):e0223944. doi:10.1371/journal.pone.0223944
   PubMed Web of Science ®Google Scholar
• Baghi A, Jabbarpoor Bonyadi MH, Ramezani A, et al. Two doses of intravitreal Ziv-Aflibercept versus bevacizumab in treatment of diabetic macular edema: a three-armed, double-blind randomized trial. Ophthalmol Retina. 2017;1(2):103–110. doi:10.1016/j.oret.2016.08.007
   PubMedGoogle Scholar
• De Oliveira Dias JR, De Andrade GC, Novais EA, et al. Fusion proteins for treatment of retinal diseases: aflibercept, Ziv-Aflibercept, and conbercept. Int J Retina Vitr. 2016;2(1):1–9.
   PubMedGoogle Scholar
• Lai IA, Hsu WC, Yang CM, Hsieh YT. Prognostic factors of short-term outcomes of intravitreal ranibizumab in diabetic macular edema. Int J Ophthalmol. 2017;10(5):765–771. doi:10.18240/ijo.2017.05.18
   PubMed Web of Science ®Google Scholar
• Fouda SM, Bahgat AM. Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema. Clin Ophthalmol. 2017;11:567–571. doi:10.2147/OPTH.S131381
   PubMed Web of Science ®Google Scholar
• De Lima Farah J, Sano R, Longo Maugéri IM, et al. Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding. Int J Retina Vitr. 2018;4(1):1–7.
   PubMedGoogle Scholar
• Hermosilla J, Pérez-Robles R, Salmerón-García A, et al. Comprehensive biophysical and functional study of Ziv-Aflibercept: characterization and forced degradation. Sci Rep. 2020;10(1):1–13. doi:10.1038/s41598-020-59465-7
   PubMed Web of Science ®Google Scholar